Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Sodium Bicarbonate in Generally Healthy People With Low Bicarbonate

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Estimated glomerular filtration rate (eGFR) ≥ 60 ml/min/1.73m2~* Urinary albumin/creatinine ratio \< 30 mg/gm~* Serum bicarbonate ≤ 23 mEq/L (average of the two most recent measurements within the past year)~* Age ≥ 50 years~Exclusion Criteria:~* Blood pressure ≥ 160/100 mm Hg~* Serum potassium \< 3.5 mEq/L~* New York Heart Association Class 3 or 4 heart failure symptoms~* Chronic oxygen therapy~* Chronic obstructive pulmonary disease requiring daily bronchodilator or prednisone therapy~* Weight ≥ 160 kg~* Use of sodium bicarbonate, sodium citrate, potassium citrate, or potassium bicarbonate within the previous two weeks.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Sodium Bicarbonate (Type: EXPERIMENTAL): All participants will receive oral sodium bicarbonate for 6 weeks (On-treatment period). After the 6 week visit, participants will stop taking sodium bicarbonate and return for a final visit 4 weeks later (Off-treatment period).~The initial dose of sodium bicarbonate prescribed is 0.3 mEq/kg/d. If a subject meets the protocol criteria, the dose will be increased to 0.6 mEq/kg/d. Half the dose will be taken by mouth in the morning and the other half in the evening.

Based on this trial design, predict the completion outcome and termination type (if applicable).